FDA Suspends Milk Testing: What It Means for Your Health
The U.S. Food and Drug Administration (FDA) has suspended its quality control program for testing fluid milk and other dairy products, citing reduced capacity in its food safety and nutrition division. This decision follows the termination and departure of 20,000 employees from the Department of Health and Human Services (HHS), part of a broader federal workforce reduction initiative.
Reuters reported, effective April 21, the U.S. Food and Drug Administration has suspended its quality testing program for Grade 'A' milk and other dairy products, citing massive staffing losses tied to federal budget cuts. While the move may seem bureaucratic, it carries potential health implications for anyone who regularly consumes dairy.
The program, which tested raw and finished milk products for contamination and safety compliance, was halted due to staffing shortages at the Moffett Center Proficiency Testing Laboratory. That facility played a central role in ensuring food labs across the country met high standards and could reliably detect harmful pathogens in your milk.
The FDA's proficiency testing programs are essential for ensuring consistency and accuracy across the nation's network of food safety laboratories. These quality control tests are also critical for laboratories to meet accreditation standards. The agency stated it is actively evaluating alternative approaches for the upcoming fiscal year and will keep participating laboratories informed as new information becomes available.
In addition to the milk testing program, the FDA has also suspended efforts to improve testing for bird flu in milk as well as for foodborne pathogens such as Cyclospora.
Without the FDA's oversight and routine quality testing, there's now a potential blind spot in the nation's food safety net—particularly when it comes to milk-borne illnesses. Contaminants like Listeria, Salmonella, E. coli, and Cyclospora can sneak into dairy products during production or packaging. Although rare, these pathogens can cause serious illness, especially for people with weakened immune systems, children, and the elderly.
And with recent headlines about bird flu particles detected in pasteurized milk, the timing isn't great. The FDA has also paused efforts to improve testing for bird flu in dairy, meaning any early-warning system is now effectively sidelined.
The FDA insists that milk sold in grocery stores is still safe. However, consumer advocates worry this rollback could reduce the agency's ability to catch emerging threats early, and that could mean less protection for you and your family.
Until full testing resumes, experts recommend sticking to well-refrigerated, pasteurized dairy products and watching expiration dates carefully.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe, who progress rapidly to end-stage heart failure. NVC-001 demonstrated significant benefits, including survival and cardiac function in preclinical models. IND clearance enables initiation of first-in-human, ascending-dose Phase 1/2 clinical trial in early 2026. SINGAPORE and PHILADELPHIA, June 10, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NVC-001. NVC-001 is an adeno-associated virus (AAV)-based gene therapy designed to treat LMNA-related dilated cardiomyopathy (LMNA DCM). Nuevocor plans to initiate an open-label, ascending-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM. "This IND clearance marks a significant milestone in our mission to develop transformative therapies for patients with genetic cardiomyopathies by leveraging unique insights from our proprietary PrOSIA mechanobiology platform," said Dr. Yann Chong Tan, co-founder and CEO of Nuevocor. "NVC-001 is the first disease-modifying therapy for LMNA DCM designed to address the underlying mechanobiological root cause of disease. We look forward to initiating our clinical trial to bring this potentially life-changing therapy to patients." LMNA DCM is a serious genetic heart condition caused by mutations in the LMNA gene, which encodes lamin A/C – a protein essential for maintaining nuclear envelope integrity and regulating gene expression in cardiac cells. Mutations in LMNA lead to a weakening of the heart muscle, arrhythmias, and progression to end-stage heart failure. LMNA DCM is estimated to affect approximately 100,000 patients in the U.S. and Europe, representing a significant unmet medical need. NVC-001 is engineered to address the functional mechanical root cause of disease by reducing aberrant mechanical stress on the nucleus, thereby restoring nuclear envelope integrity. Nuclear envelope disruption is a hallmark of LMNA DCM. In preclinical studies, treatment with NVC-001 demonstrated significant benefits, including survival and cardiac function. The planned Phase 1/2 clinical trial is a first-in-human, 52-week open-label, multicenter, ascending-dose study designed to evaluate the safety, tolerability, and preliminary efficacy of NVC-001 in adult subjects with LMNA-DCM. NVC-001 will be administered as a one-time intravenous infusion to patients in ascending-dose cohorts. About Nuevocor Nuevocor is biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with an office in the U.S. and expansion to Europe. Our unique approach, enabled by our proprietary PrOSIA mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the functional root cause of disease. Nuevocor is first-in-disease by addressing genetic cardiomyopathies that are not amendable to gene replacement therapy and have no effective treatment options. ( View original content to download multimedia: SOURCE Nuevocor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
CN Bio introduces cross-species DILI services to enhance
CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS). Building upon the Company's FDA-recognized drug induced liver injury (DILI) assay, the expanded offering enables rapid, comparative studies between commonly used animal and human models to flag interspecies differences early, and better informs in vivo study design. Traditional human in vitro methods have limited capacity to accurately determine drug toxicity. Added to this, the discrepancies between these methods and in vivo animal studies make it challenging to accurately predict safety risks for humans during preclinical testing. Often, unsafe drug candidates are wrongly progressed, and potentially life-saving ones are misclassified and abandoned, ultimately impacting clinical progression. In response to growing market demand for tools that address these concerns, CN Bio has expanded the in vitro to in vivo extrapolation (IVIVE) capabilities of its established PhysioMimix ® DILI assay, adding the ability to easily compare results across human-, rat-, and dog-derived Liver-on-a-chip models. These assays offer a modernized workflow to generate predictive and actionable insights that mitigate the risk of costly, late-stage conflicting data, and reduce unnecessary animal use by providing early warning of hepatotoxicity/DILI prior to in vivo studies. Accessible through the Company's CRS, the new offering harnesses the longstanding expertise of CN Bio's scientific team to provide detailed data analysis, optimized outcomes, and data-driven conclusions beyond what is achievable using existing in vitro models. The assay enables a broad range of longitudinal and endpoint testing for DILI-specific biomarkers from single- or repeat-dosing studies over a 14-day experimental window. This provides a more comprehensive overview of underlying mechanisms of hepatotoxicity or latent effects of drug candidates to improve IVIVE assessment and streamline clinical progression. Dr Emily Richardson, Lead Scientist, Safety and Toxicology, CN Bio, said: 'Understanding safety risks is critical to successful drug development, however, fundamental physiological and biological differences between species can lead to inaccuracies in predictions, often causing drug candidates to be wrongfully abandoned as toxic, or worse, mistakenly classified as safe.' She added: 'Having established our DILI assay as an industry leading option to garner more valuable insights across the development pipeline, we were in an ideal position to expand its capabilities and address this crucial gap in understanding hepatotoxicity using the most commonly used animal models. Partnering with us to utilize this powerful service not only ensures robust and reliable results but also provides access to a team of Organ-on-a-chip experts, who are invested in your success; to de-risk your pipeline and move it forward with confidence.'
Medscape
3 hours ago
- Medscape
Puffs, Pods, Pouches: Which Nicotine Trend Worries Experts?
On World No Tobacco Day, CHC Mont Legia hosted the clinical nurse tobacco specialist Adrien Meunier to discuss the role of next-generation nicotine products in smoking cessation. The central question is: Do these alternatives genuinely help smokers quit, or are they simply a new gateway to combustible tobacco use? Before presenting these next-generation nicotine products, Meunier dispelled the common myth that nicotine itself is not the cause of fatal diseases. The actual harm comes from thousands of toxic substances released during combustion, which are inhaled through cigarette smoke. These include tar, which is linked to lung, bladder, and pancreatic cancers, and carbon monoxide, which is associated with cardiovascular disease. In contrast, nicotine triggers the release of endorphins and dopamine in the brain, producing a sense of well-being that smokers seek. 'This clarification is essential because 79% of smokers believe nicotine is carcinogenic. Therefore, they are unlikely to use nicotine-replacement therapy when they try to quit, which heightens anxiety and potentially causes them to fail in their attempt,' Meunier said. For many years, the tobacco industry has marketed products that deliver nicotine safely. However, several of these products remain problematic. Device Debate The most well-known of these are e-cigarettes. Invented in 2010 by a Chinese pharmacist independent of major tobacco companies, the first was a box mod. The earliest model, the box mod, heated liquid to a high temperature to transform it into vapor and inhale. Because there was no combustion, the highly toxic compounds found in cigarette smoke were avoided. The liquid consisted of vegetable glycerin, propylene glycol, water, alcohol, and nicotine. 'The problem is that the nicotine is very pungent and only present in small quantities,' Meunier explained. This pungency will displease some: They will quickly return to 'classic' cigarettes. Those who are not bothered by the taste still do not get enough nicotine, so they vape constantly and consume massive amounts of liquid. However, there are hundreds of flavoring additives to give flavor, such as strawberries and watermelon, to this box mod. When heated, they release toxic furans, which are carcinogenic. Therefore, it is better to turn to neutral flavors, such as tobacco and mint. The box mod should be avoided for smoking cessation. First, because of the potentially toxic substances generated when the liquid is heated, such as furans and carbonyl compounds, and on the other hand, because of the significant differences, for instance, much less nicotine and not the same type of inhalation compared to combustible cigarettes. In addition, box mods are quite expensive, costing 80-160 euros. 'The problem is that 67% of Belgian smokers who buy e-cigarettes to quit smoking turn to this form,' Meunier said. A few years later, e-cigarettes evolved into pod form. 'Pods have smaller batteries, and you cannot adjust the power output. The liquid heats at lower temperatures, which limits the release of toxic compounds,' Meunier said. Another advantage of pod systems is that nicotine strength can be modulated. In addition, frequent coil replacement prevents heavy metal accumulation, which is a disadvantage of box mods. Among other advantages, e-cigarettes with pods contain nicotine salts at the same pH as the nicotine present in combustible cigarettes. Thus, the smoker will be able to find peaks similar to those he has known. 'For nicotine-dependent users, this is revolutionary: You get a large dose of smooth nicotine with much less vapor,' he said. Currently, there are refillable pods. 'They are cheaper, so they can be interesting for patients with fewer resources. However, the longer you keep the same coil, the greater the risk of heavy metal accumulation,' said Meunier. As with box mods, it is best to choose the most neutral flavors available. On price, pods represent a big price difference compared to e-cigarettes, with pods costing around 10 euros, while individual pods sell for only a few euros each. How to Use a Pod-Based e-Cigarette in Smoking Cessation Meunier strongly recommended the use of pod e-cigarettes to help patients quit smoking. The question remains as to how to proceed. Each cigarette delivered approximately 1 mg of nicotine. Therefore, they will need to take patches equivalent to the amount of nicotine they usually consume. A smoker of 21 cigarettes per day should use a 21 mg nicotine patch to prevent withdrawal symptoms. However, patches provide a steady dose, while smokers require nicotine 'hits.' That is where low-dose (1 mg) gum or lozenges fulfill minor cravings for smoking. A pod-based e-cigarette using the highest nicotine salts, such as 10 mg for those smoking 10-20 cigarettes daily and 20 mg for heavier smokers, addresses the major urges. 'We are offering the full menu. The patch helps calm the patient, the tablets are used for small cravings, and the e-cigarette is used for large cravings. Since the patient will already have a good dose of nicotine, they will draw less on each cigarette and can stretch one pod over 5 or 6 days,' Meunier said. Subsequently, the patches, lozenges, and pods should be tapered gradually so that the withdrawal process remains comfortable. Since nicotine is highly addictive — more so than cocaine or heroin — abrupt cessation can cause irritability and compensatory behaviors, such as excessive sugar intake. Meunier recommended two patches for each dosage: 42 days at 21 mg, 42 days at 14 mg, and 42 days at 7 mg. Youth Trend Another product that has emerged among adolescents is puffs. According to a study conducted in Belgium in 2024, 92% of young people aged 11-24 years were aware of puffs, and 39% reported using them — 81% with nicotine, often at 20 mg. 'Puffs are inexpensive, colorful, flavored, and disposable, leaving no trace for parents that can be detected,' Meunier said. Similar to e-cigarettes, puffs contain vegetable glycerin and propylene glycol; however, their nicotine salts are synthetic. Being tasteless, young consumers go unnoticed. However, they are also more addictive. 'It makes them dependent for life and causes developmental problems, such as hyperactivity or learning disorders. Moreover, puffs are a steppingstone to smoking,' Meunier warned. Slick social media marketing and a wide range of appealing flavors, such as cola, red berries, cookies, and popcorn, can give young people the impression that they are inhaling something as harmless as candy. Meanwhile, major tobacco companies are taking it a step further with new tactics such as smart vapes. This device combines nicotine addiction with elements of gambling: The more a person vapes, the more virtual currency they earn, allowing them to climb the leaderboard of other users. Recently, a new device called a puff has emerged. One version, nicknamed 'Tamagotchi,' requires users to vape to keep a virtual pet alive. Although their sales have been banned in Belgium since the beginning of the year, young people still manage to hold them. In a recent survey, many high school students said that they could easily obtain these products. They are readily available on social media and are often disguised in makeup boxes or candy bags to avoid detection by parents. 'These products are often manufactured in China under poor conditions, using low-quality components. In addition to the elevated levels of nicotine and carcinogenic substances in the liquid, the devices themselves contain harmful materials such as lead and arsenic,' added Meunier. Study Findings e-Cigarettes are less risky than combustible cigarettes but should be avoided by nonsmokers. Precise assessment of their harm is complex because studies rarely differentiate them by device type or flavor. Long-term health effects remain unknown, as e-cigarettes have existed for only 15 years, and most users are former cigarette smokers. 'We know the risks associated with ingesting propylene glycol, vegetable glycerin, and especially flavorings, but we do not know what happens when they are inhaled. We also know that we must be careful of the carbonyl compounds produced when heating to too high a temperature,' Meunier said. Recent studies show that 28% of patients who use e-cigarettes quit smoking within 6 months compared with 16% who rely on patches and lozenges alone. However, many then struggle to give up e-cigarettes because of their habitual use and nicotine dependence. 'First-line therapy, it is best to try patches and lozenges alone. If that fails, add pod-based e-cigarettes with neutral flavors,' Meunier advised. Avoided Products Meunier concluded his lecture by presenting new-generation products other than the various variants of e-cigarettes. It began with heated tobacco devices that are now entering Belgium. These devices heat real tobacco without burning it and therefore produce no smoke. However, some patients mistake e-cigarettes for containing tobacco. 'In reality, these arguments are false. This system emits smoke, which contains all the toxic and carcinogenic constituents present in combustible cigarettes. The Superior Health Council of Belgium is clear that heated tobacco cannot be used as part of a smoking cessation program. Is clear: Heated tobacco cannot be used for cessation,' he said. Another product more popular among young people than puffs is nicotine pouches, placed between the gum and lip, delivering up to 10 mg of nicotine per pouch, with some containing 50 mg, which is lethal to young children. Attractive packaging targets the youth. 'Nicotine pouches are common in football and hockey clubs for their stimulant effect. They are banned in Belgium; however, young people manage to get their hands on them through a parallel market. And it is even worse since they contain arsenic and lead,' Meunier said. He also raised concerns about a new molecule that arrived recently in Belgium, 6-methyl-nicotine. 'It is a synthetic version of nicotine and is believed to be even more addictive,' he said. It is sold under various names, such as NoNic and metatine, and can be found in disposable vapes and sachets aimed at young people. 'As you can see, it is the Wild West. Manufacturers deliberately create confusion to slip through the legal net and continue to distribute nicotine in the most attractive way possible,' concluded Meunier.
